title: HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?
authors.affiliation: Departments of Immunology & Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
authors.forename: Amer A
authors.initials: AA
authors.lastname: Beg
authors.affiliation: Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
authors.forename: Jhanelle E
authors.initials: JE
authors.lastname: Gray
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D047630:Depsipeptides / Q000008:administration & dosage; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage*; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000187:drug effects / Q000473:pathology; D051379:Mice; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends; D009369:Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000473:pathology; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D059016:Tumor Microenvironment / Q000187:drug effects / Q000276:immunology
chemical_list: D047630:Depsipeptides; D056572:Histone Deacetylase Inhibitors; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C087123:romidepsin
keywords: PD-1; T cells; T-cell chemokines; clinical trial; epigenetic agents; histone deacetylase inhibitors; immunotherapy; lung cancer; romidepsin; vorinostat